Patent GB-1429045-A (GB)
Title: Hiazole cardiovascular agents
IPC: C07D277/34
Filed: 1973-06-13
Abstract: 1429045 Thiazole derivatives SYNTEX CORP 13 June 1973 [10 July 1972] 28145/73 Heading C2C Novel thiazole derivatives of the general formula wherein each of R<SP>1</SP> and R<SP>2</SP> is a hydrogen atom or a C 1-6  alkyl, C 3-7  cycloalkyl, aryl, aralkyl, C 1-6  alkylaryl, hydroxy-C 1-6  alkyl, C 1-6  alkoxy-C 1-6  alkyl, adamantyl or heterocyclyl-C 1-6  alkyl group (the heterocyclic radical having 5-7 ring atoms, 1 or 2 of which is/are chosen from N, O and S, at least one being N, and being optionally substituted by 1 or 2 substituents selected from C 1-6  alkyl and hydroxy-C 1-6  alkyl groups and halogen atoms or a group of the formula -(CH 2 ) n -NR<SP>6</SP>R<SP>7</SP>, in which each of R<SP>6</SP> and R<SP>7</SP> is a hydrogen atom or C 1-6  alkyl group and n is 2-6, or NR<SP>1</SP>R<SP>2</SP> is a heterocyclic group having 5-7 ring atoms and 1 or 2 heteroatoms chosen from N, O and S, at least one being N, optionally substituted by 1 or 2 substituents chosen from C 1-6  alkyl and hydroxy-C 1-6  alkyl groups and halogen atoms, and pharmaceutically acceptable acid addition salts thereof are prepared (a) by reaction of the oxirane derivative of the formula with a compound of the general formula R<SP>1</SP>R<SP>2</SP>NH; or (b) when one of R<SP>1</SP> and R<SP>2</SP> is a hydrogen atom and the other is a hydrogen atom or a C 1-6  alkyl, aryl or aralkyl group, by hydrolysis of an oxazolidine derivative of the general formula wherein R<SP>3</SP> is a hydrogen atom or a C 1-6  alkyl, aryl or aralkyl group; followed optionally by salification of the product. Novel oxazolidine derivatives of the general formula wherein each of R<SP>4</SP> and R<SP>5</SP> is a hydrogen atom or a C 1-6  alkyl or aralkyl group or R<SP>4</SP> and R<SP>5</SP>, together with the carbon atom to which they are attached, form a C 5-7  cycloalkane ring, are prepared (i) when each of R<SP>4</SP> and R<SP>5</SP> is a hydrogen atom, by reaction of a 5-hydroxymethyl oxazolidine of the general formula with 5-bromo- or chloro-thiazole; or (ii) by treatment of a thiazole derivative (I) wherein one of R<SP>1</SP> and R<SP>2</SP> is a hydrogen atom and the other is a hydrogen atom or a C 1-6  alkyl, aryl or aralkyl group, with R<SP>4</SP>R<SP>5</SP>CO and aluminium isopropoxide. The oxirane derivative (II) is prepared by reaction of 5-bromo- or chloro-thiazole with glycerol acetonide in the presence of an alkali metal hydride, treatment of the resulting 3- (thiazol-5-oxy)-propane 1,2-acetonide with an acid, and treatment of the resulting 3-(thiazol- 5-oxy)-1,2-propanediol with an alkane- or benzene-sulphonyl chloride or bromide, followed by a strong base. 5-Bromothiazole is prepared by diazotization of 2-amino-5-bromothiazole, followed by treatment with aqueous hypophosphorous acid. 5-Hydroxymethyloxazolidines (B<SP>1</SP>) are prepared by treatment of glycidol with R<SP>3</SP>NH 2 , followed by formaldehyde. Pharmaceutical compositions, useful in the treatment and palliation of cardiovascular abnormalities, comprise, as active ingredient, a thiazole derivative (I) or a pharmaceutically acceptable acid addition salt thereof or an oxazolidine derivative (III), together with a pharmaceutically acceptable carrier.